IMEIK: Termination conditions have been triggered, and South Korea's REGEN has terminated the exclusive agency agreement as agreed

Investors have asked that Regen terminate the contract on the grounds of 'Datuo Medical transferring its business to Jiangsu Wuzhong Meisheng Biotechnology Company' and '*ST Suwu's financial fraud damaging brand reputation'. Please explain the **specific contract terms and legal basis for Regen's claims regarding these two termination conditions, and how the company justifies their reasonableness? IMEIK stated on the interactive platform that the termination conditions regarding the prohibition of business transfer and others stipulated in the exclusive distribution agreement have been triggered, and that Korean REGEN has terminated the exclusive agency agreement as agreed